ClinicalTrials.gg
RecruitingNCT04155112MeDiPAUpdated May 9, 2023

Hypocaloric Mediterranean Diet or Physical Activity to Lower Cardiometabolic Risk

An interventional study of Physical activity and Hypocaloric Mediterranean diet in Overweight or Obesity, Obesity, Abdominal and Hypertension, sponsored by Oslo University Hospital. Recruiting at 1 site in Norway. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-05-09.

Primary conditionObesity, AbdominalRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity, Abdominal
Why
  1. The study's listed conditions name Obesity, Abdominal, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Oslo University Hospital · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2024, 2 years 1 month ago, but the record still lists the study as recruiting.
  • Started Apr 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The purpose of this randomized controlled trial is to test the effects of a hypocaloric Mediterranean diet or of physical activity in participants who take at least 2 antihypertensive drugs but do not reach blood pressure treatment goal.

This study is a randomized, controlled, single-center, parallel group trial with three arms: hypocaloric Mediterranean diet (MeDi), physical activity (PA), or control. The control group will receive usual care (no intervention). This study will not be blinded.

The interventions will last 6 months, while the study follow-up will last 12 months. Four study visits will take place: baseline, at 3 months, at 6 months, at 12 months. The primary outcome is change in mean 24-hour ambulatory systolic blood pressure and diastolic blood pressure among groups after 6 months of intervention. Secondary and exploratory outcomes include change in other measures of blood pressure, body composition, other markers of cardiometabolic disease, inflammation markers, safety outcomes, and quality of life, among others.

02

Conditions studied

  • Overweight or Obesity
  • Obesity, Abdominal
  • Hypertension

Keywords

  • Hypertension
  • Lifestyle
  • Mediterranean diet
  • Physical activity
  • Weight loss
03

In context

Obesity, Abdominal Reclassified

295 studies on the registry are indexed under Obesity, Abdominal; 45 are open to participants now.

This study's planned enrollment of 90 is above the median of 58 across 235 interventional studies indexed under Obesity, Abdominal.

Browse Obesity, Abdominal studies →

Lead sponsor

Oslo University Hospital is the lead sponsor of 835 studies on the registry; 148 are open to participants now.

Compared within Obesity, Abdominal, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women
  • 18 - 70 years
  • Taking ≥ 2 antihypertensive drugs (includes combination therapy)
  • Office SBP ≥ 140mmHg and/or DBP ≥ 90mmHg on two occasions
  • 25 - 40 kg/m2
  • Waist circumference ≥ 88 cm (women) or ≥ 102 cm (men)
  • Sedentary lifestyle (\< 150 minutes/week of moderate intensity physical activity)
  • Weight stable (± 5 kg in the last 6 months)
  • Not on a weight loss diet
  • Willing to comply to an intervention of either a hypocaloric Mediterranean diet or physical activity (or control) for 6 months

Exclusion criteria

Exclusion Criteria:

  • Unable to provide
  • Pregnant or lactating
  • Office BP ≥ 160/100 mmHg
  • Diabetes mellitus type 1
  • History of cardiovascular disease (including uncompensated heart failure, recent infarction or stroke in the last 6 months, severe arrhythmia, heart failure or unstable angina pectoris)
  • Chronic kidney disease stages 4 or 5
  • Cancer in the last 5 years
  • Changes in concurrent medication (anti-hypertensives, anti-diabetics, lipid-lowering drugs) in the last 3 months
  • Regular use of oral in excess of 5 mg prednisolone (or equivalent) during the last month
  • Use of GLP-1 analogues for \< 1 year
  • Drug or alcohol abuse
  • Eating disorders or severe dietary restrictions
  • Impediments to physical activity at recommended levels due to musculoskeletal and other conditions.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Physical activity (PA)

    For 6 months, the participants will be recommended to increase physical activity to ≥ 150 min of moderate intensity or ≥ 75 min of vigorous intensity aerobic PA (or an equivalent combination) and ≥ 2 days of resistance exercise a week. The participants will take part in supervised group classes, twice per week. Each participant will receive a heart rate monitor to bring home and to use while reporting activity via a physical activity diary.

    Behavioral: Physical activity

  • Experimental
    Hypocaloric Mediterranean diet (MeDi)

    For 6 months, the participants will be recommended to consume a diet for 5-10% body weight loss. This diet will be based on the Mediterranean diet pattern. For the 6 months of the intervention, the participants will weigh themselves weekly and report their progress to the investigator. Adaptations to the diet will be made to ensure the goal of 5-10% weight loss is achieved. Each participant will receive a scale to bring home and to use while reporting weight loss.

    Behavioral: Hypocaloric Mediterranean diet

  • No intervention
    Control

    At baseline, participants will receive usual care, which consists of general information regarding the importance of lifestyle for BP. This information will not be reinforced throughout the study duration.

Interventions

  • BehavioralPhysical activity

    Increased physical activity to the minimum recommended by health authorities (≥ 150 min of moderate intensity or ≥ 75 min of vigorous intensity aerobic PA (or an equivalent combination) and ≥ 2 days of resistance exercise a week).

    Also known as: PA

  • BehavioralHypocaloric Mediterranean diet

    Energy deficit to reach 5-10% weight loss within 6 months, based on the Mediterranean diet pattern.

    Also known as: MeDi

06

What researchers measure

Primary outcomes

  1. Change in 24-hour ambulatory SBP among subjects, after 6 months.

    24-hour ambulatory blood pressure will be measured with a device that allows free-living. Change = (6 month measurement - baseline measurement).

    Time frame: Baseline to 6 months

  2. Change in 24-hour ambulatory DBP among subjects, after 6 months.

    24-hour ambulatory blood pressure will be measured with a device that allows free-living. Change = (6 month measurement - baseline measurement).

    Time frame: baseline to 6 months

Secondary outcomes

  1. Change in other measures of blood pressure, within and among subjects, after 6 and 12 months.

    Blood pressure will be measured with 24-hour ambulatory blood pressure monitors and in-office. Other measures of blood pressure include daytime blood pressure, nighttime blood pressure, and office systolic and diastolic blood pressure. Change = (6 or 12 month measurement - baseline measurement)

    Time frame: Baseline to 6 months, baseline to 12 months

  2. Change in body composition, within and among subjects, after 6 months.

    Office measures of body composition will include weight, waist and hip circumferences, BMI, waist-to-hip ratio, and bioimpedance analysis (BIA). Additional measures of body composition will be acquired via Dual-energy X-ray absorptiometry (DXA), including fat mass, fat-free body mass, visceral adipose tissue, subcutaneous adipose tissue, and bone mineral content and density. Change = (6 month measurement - baseline measurement)

    Time frame: Baseline to 6 months

  3. Change in markers of cardiometabolic risk, within and among subjects, after 6 and 12 months.

    Cardiometabolic risk factors (including measures of glucose regulation, blood lipids, NORRISK 2 score, metabolic syndrome) will be measured via blood samples and additional clinical parameters. Change = (6 or 12 month measurement - baseline measurement)

    Time frame: Baseline to 6 months, baseline to 12 months

  4. Change in inflammation markers, within and among subjects, after 6 and 12 months.

    Inflammation markers will be measured via blood tests (including CRP and differential leucocyte count). Change = (6 or 12 month measurement - baseline measurement)

    Time frame: Baseline to 6 months, baseline to 12 months

  5. Change in safety outcomes, within and among subjects, after 6 and 12 months.

    Safety outcomes will be measured via blood tests (including hematology, kidney, liver, and thyroid markers). Change = (6 or 12 month measurement - baseline measurement)

    Time frame: Baseline to 6 months, baseline to 12 months

Other outcomes

  1. Change in quality of life, within and among subjects, after 3, 6 and 12 months.

    Quality of life will be measured via the EQ-5D questionnaire.

    Time frame: Baseline to 6 months, baseline to 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Oct 2024, 18 months after the start.

Of 107 non-industry interventional studies with no phase under Obesity, Abdominal, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 29. This study's planned 18 months is above that.

Counting every sponsor, half of 117 studies reached it within 16 months; a quarter within 7 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2019
First posted
Nov 7, 2019
StartActual
Apr 21, 2023
Primary completionEst.
Oct 2024
CompletionEst.
Sep 2025
Last update
May 9, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04155112
Collaborators
The National Association for Public Health, Norway
Responsible party
Kari Anne Sveen (MD, PhD, Oslo University Hospital) — Principal investigator
First posted
Nov 7, 2019
Start date
Apr 21, 2023
Primary completion
Oct 2024 (estimated)
Completion
Sep 2025 (estimated)
Last update
May 9, 2023

Study contacts

Kari Anne Sveen, MD, PhD
Contact
kasvee@ous-hf.no
0047 915 02 770
Ana Sousa, MSc
Contact
anaseq@ous-hf.no
0047 230 33 588
Kari Anne Sveen, MD, PhD
study chair · Oslo University Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion